VIDEO: Aflibercept 8 mg shows continued anatomic improvements, safety at 96 weeks

Issue: March 10, 2024

BySunir J. Garg, MD

ByAnthony DeFino

Fact checked byEamon N. Dreisbach

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye 2024, Sunir J. Garg, MD, FACS, FASRS, discusses 96-week data investigating aflibercept 8 mg for the treatment of neovascular age-related macular degeneration.

“What I am telling my patients is that we can use a drug that we have become very familiar with over the past 10 years,” he said. “We are getting similar anatomic response and over time patients were able to be dosed a lot less frequently.”

Published by:

Sources/Disclosures

Collapse

Source:

Garg S. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 96-week results from the phase 3 PULSAR trial. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Disclosures: Garg reports consulting for and receiving research grants from Regeneron.

Hawaiian Eye/Retina Meeting

Read more

VIDEO: Aflibercept 8 mg shows continued anatomic improvements, safety at 96 weeks

Related Content